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Psoriasis has been linked to cardiometabolic diseases, but epidemiological findings are inconsistent. We
investigated the association between psoriasis and cardiometabolic outcomes in a German cross-sectional study
(n¼ 4,185) and a prospective cohort of German Health Insurance beneficiaries (n¼ 1,811,098). A potential genetic
overlap was explored using genome-wide data from422,000 coronary artery disease and44,000 psoriasis cases,
and with a dense genotyping study of cardiometabolic risk loci on 927 psoriasis cases and 3,717 controls. After
controlling for major confounders, in the cross-sectional analysis psoriasis was significantly associated with type 2
diabetes (T2D, adjusted odds ratio (OR)¼ 2.36; 95% confidence interval CI¼ 1.26–4.41) and myocardial infarction
(MI, OR¼ 2.26; 95% CI¼ 1.03–4.96). In the longitudinal study, psoriasis slightly increased the risk for incident T2D
(adjusted relative risk (RR)¼ 1.11; 95% CI¼ 1.08–1.14) and MI (RR¼ 1.14; 95% CI¼ 1.06–1.22), with highest risk
increments in systemically treated psoriasis, which accounted for 11 and 17 excess cases of T2D and MI per 10,000
person-years. Except for weak signals from within the major histocompatibility complex, there was no evidence
of genetic risk loci shared between psoriasis and cardiometabolic traits. Our findings suggest that psoriasis, in
particular severe psoriasis, increases the risk for T2D and MI, and that the genetic architecture of psoriasis and
cardiometabolic traits is largely distinct.
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INTRODUCTION
Psoriasis is one of the most common chronic inflammatory
skin diseases and affects 2–4% of the general population with,
however, variations between and within countries (Parisi
et al., 2013), and causes a significant social and pharmaco-
economic burden (Suarez-Farinas et al., 2012). Experimental
data indicate that chronic skin inflammation has a systemic
component, affects different metabolic pathways, and drives
inflammation in other tissues (Wang et al., 2012). In line with
this concept, epidemiological studies reported an elevated risk
for inflammatory comorbidities such as cardiovascular disease
(CVD) and metabolic diseases, in particular in younger
individuals with severe psoriasis–that is, those with a higher
genetic component (Gelfand et al., 2006; Lu et al., 2013;
Miller et al., 2013; Shaharyar et al., 2014). However, most
published studies were carried out in selected populations and
suffer from methodological limitations such as insufficient
phenotyping and incomplete adjustment for potential
confounders. Further, results on cardiometabolic risk factors
associated with psoriasis are inconsistent (Armstrong et al.,
2013; Miller et al., 2013; Samarasekera et al., 2013). Results
from disease-by-disease gene mapping indicate a considerable
overlap in the genetic basis of different immune-mediated
diseases (Zhernakova et al., 2013), and data from candidate
gene studies suggest that some genetic variants associated
with the risk of inflammatory diseases, e.g. rheumatoid
arthritis, also predispose to cardiovascular and metabolic
diseases (Krawczak et al., 2006; Ellinghaus et al., 2012; Lieb
and Vasan, 2013). However, comprehensive analyses on the
potential overlap in the genetic architectures of psoriasis and
cardiometabolic traits are lacking. In the current study, we
aimed to analyze the association between psoriasis and
cardiometabolic risk factors and clinical disease outcomes
using two different epidemiological data sets: the population-
based Cooperative Health Research in the Region of Augsburg
(KORA) study (n¼4,185) and data from German Health
insurance beneficiaries (n¼ 1,811,098). Furthermore, we
performed comprehensive genetic analyses in order to assess
whether and to which degree the genetic architectures of
psoriasis and CVD overlap. To this end, we carried out in
silico analyses of genetic coronary artery disease (CAD) and
psoriasis risk variants identified through genome-wide associa-
tion studies (GWAS) in 422,000 CVD cases, 44,000
psoriasis cases, and 460,000 controls. In addition, we used
the Metabochip custom array to densely genotype and
analyze established cardiometabolic risk loci in a set of 927
psoriasis cases and 3,717 controls.
RESULTS
Cross-sectional association of psoriasis with cardiometabolic
traits in KORA
The prevalence of psoriasis in the KORA study sample
including German adults (n¼4,185; mean age 56 years,
48.5% men) was 4.8%, which is slightly above the prevalence
reported from German secondary health care data on adults of
the same age range (4%) (Schafer et al., 2011). This might in
part be attributable to mild cases that may not seek medical
attention (Table 1). In terms of the cardiovascular risk factor
profile, individuals with psoriasis were less likely to be never
smokers (36.7 vs. 45.4%), had a higher educational attainment
(education X11 years; 29.2 vs. 22.7%), had higher waist
circumference (98 vs. 93 cm), and had higher levels of
C-reactive protein (6.3 vs. 5.9 n nl-1) and leukocyte count
(1.7 vs. 1.2 mg l-1) as compared with individuals without
psoriasis. No statistically significant differences in body mass
index, blood pressure, total cholesterol-to-high-density lipo-
protein cholesterol ratio, or carotid intima-media thickness
were observed between individuals with and those without
psoriasis. In multivariable linear regression analysis psoriasis
was statistically significantly associated with waist circumfer-
ence (b¼1.70; 95% confidence interval (CI)¼0.14–3.26),
type 2 diabetes (T2D) (OR¼2.36; 95% CI¼ 1.26–4.41), and
myocardial infarction (MI) (OR¼2.26; 95% CI¼1.03–4.96),
but not with hypertension, metabolic syndrome, angina
pectoris (AP), or peripheral arterial disease (Table 2, Supple-
mentary Table S1 online). No evidence for effect modification
by age was observed (all P for interaction 40.05).
Longitudinal association of psoriasis with incident
cardiometabolic events in German Health Insurance
beneficiaries
A total of 44,623 patients with prevalent psoriasis in 2005/
2006 and 1,766,475 individuals without psoriasis were
followed up for incident cardiometabolic end points from
2007 to 2012 with a median follow-up time of 6 years.
Participant characteristics are provided in Table 3. In the fully
adjusted model, patients with psoriasis had a significantly
increased relative risk (RR) for T2D (RR¼1.11; 95% CI:
1.08–1.14), AP (RR¼ 1.27; 95% CI¼1.20–1.34), and MI
(RR¼1.14; 95% CI¼1.06–1.22) compared with patients
without psoriasis (Table 4, Supplementary Table S2 online).
After adjusting for age, sex, cardiovascular risk factors, and
comorbidities, psoriasis accounted for an excess risk of 17.89
incident cases of T2D, 10.43 incident cases of AP, and 3.25
incident MIs per 10,000 person-years. The association of
psoriasis with MI was not modified by age (P for interaction
40.05). However, we observed effect modification by age for
T2D (P for interaction¼ 4.21036), AP (P for interaction¼
0.026), and stroke (P for interaction¼ 3.2104). Specifi-
cally, we observed evidence for a decreasing strength of
association between psoriasis and incident diabetes (multi-
variable adjusted RRs (95% CI) for agep40 years: 1.27 (1.06,
1.52); for age 41–60 years: 1.10 (1.04, 1.16); and for age460
years: 1.04 (1.00, 1.07)). For stroke, stratified analyses do not
suggest a qualitative or quantitative linear association (for age
p60 years: 1.03 (0.89, 1.19); for age 61–70 years: 1.20 (1.07,
1.34); and for age 470 years: 1.07 (1.00, 1.13)). The
association between AP and psoriasis increased with increas-
ing age categories (for agep60 years: 1.16 (1.04, 1.29); for
age 61–70 years: 1.21 (1.08, 1.35); and for age 470 years:
(1.25 (1.16, 1.35)).
In sensitivity analyses the risk increments were markedly
higher in psoriasis patients receiving systemic treatment,
which is often used as a proxy for severe psoriasis
(Gelfand et al., 2006) (Table 4). Systemically treated psoriasis
(see Supplementary Table S3 online in the Supplementary
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Table 1. Characteristics1 of the analytical study population of KORA survey participants (n¼ 4,185)
No psoriasis (n¼3986) Psoriasis (n¼199) P-value2
Age, years 56 (45, 67) 56 (46, 65) 0.971
Male, n (%) 1918 (48.1) 110 (55.3) 0.049
Smoking status, n (%)
Never 1808 (45.4) 73 (36.7) 0.016
Former 1466 (36.8) 87 (43.7) 0.048
Current 712 (17.9) 39 (19.6) 0.534
Education, n (%)3
p9 years 2075 (52.1) 100 (50.3) 0.619
10 years 1001 (25.1) 41 (20.6) 0.151
X11 years 905 (22.7) 58 (29.2) 0.035
Alcohol intake, g per day 5.7 (0.0, 20.9) 5.7 (0.0, 28.6) 0.299
Physical activity, n (%)4
No activity 933 (23.4) 49 (24.6) 0.623
Low activity 523 (13.1) 32 (16.1) 0.230
Moderate activity 1557 (39.1) 75 (37.7) 0.698
High activity 973 (24.4) 43 (21.6) 0.368
BMI, kg m-2,5 26.9 (24.2, 30.1) 27.6 (24.5, 30.4) 0.117
Waist circumference, cm6 93 (84, 103) 98 (87, 105) 0.003
Systolic blood pressure, mm Hg 123 (111, 136) 123 (111, 136) 0.727
Diastolic blood pressure, mm Hg 76 (70, 84) 77 (71, 84) 0.423
Hypertension, n (%) 1704 (42.8) 91 (45.7) 0.407
Hypertension treatment, n (%) 1188 (29.8) 60 (30.2) 0.917
Total cholesterol-to-HDL cholesterol ratio 3.9 (3.1, 4.7) 3.9 (3.3, 5.1) 0.080
Lipid-lowering treatment, n (%) 463 (11.6) 29 (14.6) 0.206
Type 2 diabetes, n (%) 207 (5.2) 21 (10.6) 0.001
Type 2 diabetes treatment, n (%) 169 (4.2) 17 (8.5) 0.004
Metabolic syndrome, n (%)7 993 (35.2) 51 (40.2) 0.253
Myocardial infarction, n (%) 101 (2.5) 11 (5.5) 0.011
Peripheral arterial disease, n (%)8 196 (6.9) 14 (9.0) 0.315
Angina pectoris, n (%)9 194 (4.9) 12 (6.1) 0.450
Carotid intima-media thickness10 0.8 (0.7, 0.9) 0.8 (0.7, 0.9) 0.684
CRP, mg l-1,11 1.2 (0.6, 2.6) 1.7 (0.8, 3.5) 0.001
Leukocytes, n nl-19 5.9 (5.0, 7.1) 6.3 (5.1, 7.4) 0.024
Abbreviations: BMI, body mass index; CRP, C-reactive protein; HDL, high-density lipoprotein; KORA, Cooperative Health Research in the Region of Augsburg.
1Values are median (25th and 75th percentile) or n (percent).
2Based on Wilcoxon–Mann–Whitney test for continuous variables and w2-test for categorical variables.
3n¼4180.
4Defined as: no activity (no sports in summer or winter season), low activity (engaging in sportso1 h per week in summer or winter season), moderate activity
(engaging in sports 1–2 h per week regularly in summer or winter season), high activity (engaging in sports 42 h per week in summer and winter season).
5n¼4167.
6n¼4173.
7n¼2948.
8n¼2990.
9n¼4182.
10Average of right and left common carotid artery; n¼2646.
11n¼3024.
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Data online) accounted for B41, 17, and 11 excess cases of
AP, MI, and T2D, respectively, per 10,000 person-years
(Table 4).
Association analysis of established CAD risk SNPs with psoriasis
Except for two polymorphisms that map to HLA-C/HCG27
(rs2894181) and C6orf10/BTNL2 (rs6932542), none of the
established CAD-single nucleotide polymorphisms (SNPs) was
significantly associated with psoriasis after conservative
Bonferroni correction for multiple testing (see Supplementary
Table S4 online in the Supplementary Data online). Both
major histocompatibility complex (MHC) polymorphisms
represented signals independent from the major psoriasis
HLA-C*0602 risk allele, an observation reported before
(Feng et al., 2009; Davies et al., 2012). Effects on CAD
and psoriasis risk were in the same direction, but the
reported effect sizes on CAD were modest (ORo1.2) (Lu
et al., 2012).
Table 2. Multivariable-adjusted beta coefficient or odds ratio (OR; 95% confidence interval in parentheses)1 for
cardiometabolic outcomes by psoriasis status (n¼ 4,185)
Psoriasis, beta coefficient or OR (95% CI)
Model 1 Model 2
Continuous outcomes
BMI, kg m-2 0.51 ( 0.14, 1.16)2 0.44 (0.17, 1.05)3
Waist circumference, cm 2.03 (0.36, 3.70)4 1.70 (0.14, 3.26)5
Systolic blood pressure, mm Hg 0.09 ( 2.56, 2.38)  0.04 (2.49, 2.40)6
Diastolic blood pressure, mm Hg 0.48 ( 0.98, 1.95) 0.67 (0.78, 2.13)6
Total cholesterol-to-HDL cholesterol ratio 0.15 ( 0.01, 0.31) 0.16 (o0.01, 0.32)6
Carotid intima-media thickness 0.01 ( 0.03, 0.01)7  0.01 (0.03, 0.01)8
CRP, mg l-1 0.46 ( 0.46, 1.37)9 0.29 (0.62, 1.20)10
Leukocytes, n nl-1 0.20 ( 0.06, 0.46)11 0.16 (0.09, 0.41)12
Dichotomous outcomes
Hypertension 1.15 (0.83, 1.59) 1.08 (0.77, 1.50)6
Type 2 diabetes 2.31 (1.41, 3.80) 2.37 (1.40, 4.02)6
Metabolic syndrome 1.25 (0.85, 1.85)13 1.25 (0.85, 1.86)14
Myocardial infarction 2.29 (1.17, 4.46) 2.26 (1.03, 4.96)6
Peripheral arterial disease 1.46 (0.82, 2.60)115 1.19 (0.64, 2.22)16
Angina pectoris 1.33 (0.72, 2.44)17 1.22 (0.65, 2.27)12
Abbreviations: BMI, body mass index; CRP, C-reactive protein; HDL, high-density lipoprotein.
1Beta coefficient for continuous outcomes or OR for binary outcomes. Model 1 was adjusted for sex and age (continuous). Model 2 was adjusted for sex, age
(continuous), smoking status (never, former, current), years of education (p9 years, 10 years, orX11 years), alcohol intake (continuous), physical activity (no
activity, low activity, moderate activity, high activity), systolic blood pressure (continuous; except systolic, diastolic blood pressure, hypertension and
metabolic syndrome), hypertension treatment (no, yes; except hypertension and metabolic syndrome), type 2 diabetes (no, yes; except type 2 diabetes and
metabolic syndrome), type 2 diabetes treatment (no, yes; except type 2 diabetes and metabolic syndrome), lipid-lowering treatment (no, yes; except metabolic
syndrome).
2n¼4167.
3n¼4162.
4n¼4173.
5n¼4168.
6n¼4180.
7n¼2646.
8n¼2642.
9n¼3024.
10n¼3019.
11n¼4182.
12n¼4177.
13n¼2948.
14n¼2943.
15n¼2990.
16n¼2987.
17n¼4182.
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Association analysis of established psoriasis risk SNPs with CAD
None of the established psoriasis risk SNPs was significantly
associated with CAD after conservative Bonferroni correction
for multiple testing (see Supplementary Table S5 online and
Supplementary Figure S1 online in the Supplementary Data
online). Suggestive evidence for association (Po0.05) was
observed for three SNPs (rs1265181, rs12191877, rs10484554)
at the major psoriasis locus PSORS-1 in the MHC. These three
polymorphisms are in moderate to strong linkage disequili-
brium with the psoriasis HLA-C*0602 risk allele (r2X0.6) and
show weak opposing effects on CAD risk. Further suggestive
evidence for association with CAD was observed for a variant
near the interleukin enhancer-binding factor 3 (ILF3) and
coactivator-associated arginine methyltransferase 1 (CARM1)
genes (P¼ 1.7410 3).
Proportion of CAD SNPs associated with psoriasis and vice versa
In 61.7% of the investigated psoriasis SNPs the same risk
alleles showed a positive association (OR41) with CAD,
which is in the range of expectation by chance (P¼ 0.1439).
In the reverse comparison, in 65.5% of the CAD SNPs the
same risk allele showed a positive association with psoriasis,
which is slightly more than the expected 50% by chance
(P¼ 0.030). However, none of these SNPs showed nominal
significance (Po0.05).
Metabochip analysis in the psoriasis case-control study
Multiple SNPs from within the MHC locus displayed
a strong association with psoriasis. The top SNP was
rs10484554 (see Supplementary Table S6 online in the
Supplementary Data online), which tags the HLA-C*0602
risk allele (P¼5.841016, OR¼ 2.03, 95% CI¼ 1.86–
2.20) (Figure 1). Conditioning upon rs10484554, the P-values
for all other SNPs at the MHC locus were substantially
mitigated, which, however, could be due to a lack of
power given that robust evidence for several independent
signals from within the MHC has been provided in
previous studies (Knight et al., 2012). No non-MHC SNP
exceeded the conservative array-wide significance level
(P¼ 5.03 10 7). Suggestive evidence for association
(Po5 106) was observed for five loci comprising the
genes TMEM2, ZMIZ1, ARHGAP42, and two intergenic
regions (see Supplementary Table S7 online in the
Supplementary Data online). Of the 43 previously reported
psoriasis susceptibility loci (Hindorff et al.), 32 reached
nominal significance (Po0.05) in the Metabochip analysis.
No association was seen for the loci IL28RA, LCE3D,
B3GNT2, ZDHHC23, TNFAIP3, TAGAP, ELMO1, ZC3H12C,
SDC4, and UBE2l3, which, however, are sparsely covered by
the Metabochip (see Supplementary Table S8 online in the
Supplementary Data online).
Table 3. Characteristics1 of the allgemeine ortskrankenkasse Saxony database by psoriasis status (n¼ 1,811,098)
Psoriasis P-value2
No Psoriasis
(n¼ 1,766,475)
No
medication
(n¼ 9,213)
Exclusively topical
medication
(n¼31,139)
Systemic
medication
(n¼ 4,271)
Total
(n¼44,623)
Psoriasis versus
no Psoriasis
Age (years) in 2005 49 (30, 68) 57 (43, 70) 61 (45, 72) 54 (42, 66) 59 (44, 71) o1E–300
Male, n (%) 811,180 (45.9) 4,384 (47.6) 14,343 (46.1) 2,020 (47.3) 20,747 (46.5) 0.016
Hypertension, n (%)3,4 205,831 (19.5) 1,063 (26.3) 3,682 (28.9) 580 (29.7) 5,325 (28.4) 1.3E–204
Type 2 diabetes, n (%)3,5 120,507 (8.1) 787 (11.3) 2,860 (12.6) 394 (12.0) 4,041 (12.3) 2.1E–162
Myocardial infarction, n (%)3,6 20,103 (1.2) 143 (1.6) 574 (1.9) 80 (1.9) 797 (1.9) 3.2E–39
Peripheral arterial disease, n (%)3,7 31,138 (1.8) 234 (2.7) 918 (3.1) 103 (2.5) 1,255 (3.0) 1.8E–68
Angina pectoris, n (%)3,8 32,350 (1.9) 251 (3.0 ) 959 (3.4) 125 (3.2) 1,335 (3.3) 2.4E–82
Stroke, n (%)3,9 41,778 (2.5) 289 (3.3) 1,134 (3.9) 113 (2.7) 1,536 (3.6) 3.8E–54
Obesity, n (%)3,10 102,601 (6.7) 578 (7.8) 2,172 (8.8) 362 (10.8) 3,112 (8.8) 3.0E–53
Disorders of lipoprotein metabolism
and other lipidemias, n (%)3,11
165,526 (11.8) 1,045 (16.7) 3,584 (16.8) 517 (17.1) 5,146 (16.8) 4.3E–158
Mortality, n (%)3 174,642 (9.9) 1,076 (11.7) 4,272 (13.7) 371 (8.7) 5,719 (12.8) 1.3E–92
1Values are given as median (25th and 75th percentile) or n (percentage).
2Based on the Wilcoxon–Mann–Whitney test for age and the w2-test for categorical variables.
3Incidence in 2007–2012.
4n¼1,075,121.
5n¼1,514,541.
6n¼1,773,833.
7n¼1,751,381.
8n¼1,715,269.
9n¼1,746,355.
10n¼1,567,015.
11n¼1,436,629.
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Table 4. Multivariable-adjusted relative risk (RR; 95% confidence interval in parentheses) and excess risk per 10,000
person-years1 for cardiometabolic diseases by psoriasis status (n¼ 1,811,098)
RR (95% CI) Excess risk per 10,000 person-years2
Model 1 Model 2 Model 1 Model 2
Type 2 diabetes 2007–20123
Psoriasis (present vs. absent) 1.21 (1.18, 1.25) 1.11 (1.08, 1.14) 34.16 17.89
Psoriasis, no medication 1.16 (1.08, 1.23) 1.06 (0.99, 1.13) 26.03 9.76
Psoriasis, exclusively topical medication 1.21 (1.17, 1.25) 1.10 (1.07, 1.14) 34.16 16.27
Psoriasis, systemic medication 1.38 (1.26, 1.51) 1.25 (1.14, 1.37) 61.81 40.67
Myocardial infarction 2007–20124
Psoriasis (present vs. absent) 1.24 (1.15, 1.33) 1.14 (1.06, 1.22) 5.58 3.25
Psoriasis, no medication 1.10 (0.94, 1.30) 1.01 (0.86, 1.19) 2.32 0.23
Psoriasis, exclusively topical medication 1.23 (1.14, 1.34) 1.13 (1.05, 1.23) 5.34 3.02
Psoriasis, systemic medication 1.62 (1.30, 2.01) 1.48 (1.19, 1.84) 14.40 11.15
Angina pectoris 2007–20125
Psoriasis (present vs. absent) 1.38 (1.30, 1.45) 1.27 (1.20, 1.34) 14.68 10.43
Psoriasis, no medication 1.29 (1.14, 1.46) 1.17 (1.04, 1.33) 11.21 6.57
Psoriasis, exclusively topical medication 1.38 (1.29, 1.47) 1.28 (1.20, 1.36) 14.68 10.82
Psoriasis, systemic medication 1.57 (1.32, 1.86) 1.43 (1.21, 1.70) 22.03 16.62
Stroke 2007–20126
Psoriasis (present vs. absent) 1.17 (1.11, 1.23) 1.11 (1.06, 1.17) 8.34 5.39
Psoriasis, no medication 1.10 (0.99, 1.24) 1.05 (0.94, 1.18) 4.90 2.45
Psoriasis, exclusively topical medication 1.19 (1.12, 1.26) 1.13 (1.07, 1.20) 9.32 6.37
Psoriasis, systemic medication 1.14 (0.95, 1.36) 1.08 (0.90, 1.29) 6.86 3.92
1Model 1 was adjusted for sex and age (continuous). Model 2 was adjusted for sex, age (continuous), hypertonia (no, yes), type 2 diabetes (no, yes; except type
2 diabetes), obesity and disorders of lipoprotein metabolism and other lipidemias (no, yes).
2Excess risks calculated on the basis of adjusted risk ratios.
3n¼1,514,541.
4n¼1,773,833.
5n¼1,715,269.
6n¼1,746,355.
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Figure 1. Manhattan plot of Metabochip results on psoriasis.
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DISCUSSION
Main findings
Using different large-scale epidemiological and genetic data
sets, we assessed the interrelation of psoriasis and cardiometa-
bolic outcomes as well as a potential common genetic
underpinning of these traits. In both our cross-sectional and
cohort study, psoriasis was an independent yet modest risk
factor for T2D and MI. Sensitivity analyses in the cohort study
provided evidence for a ‘‘dose–response’’ association as
severe psoriasis was associated with higher risks for T2D,
AP, and MI relative to mild psoriasis. Except for two psoriasis
risk loci from within the MHC with small effects (ORo1.2) on
CAD risk, none of the established psoriasis risk polymorphisms
showed a robust association with CAD, and no gene variant
previously associated with CAD was robustly associated with
psoriasis. Likewise, while confirming the vast majority of
known psoriasis risk loci, our dense genotyping study did
not indicate that validated loci for cardiometabolic traits have
a notable effect on psoriasis risk, although we cannot rule out
the probability that we may have missed rare variants or
variants with minor effects.
In the context of the published literature
The first study that claimed an increased cardiovascular risk in
patients with psoriasis stems from a large prospective, popula-
tion-based cohort study using UK electronic medical record
data (Gelfand et al., 2006). Subsequently, a series of multiple
studies reported a higher risk for various cardiometabolic traits
(including hypertension, T2D, hyperlipidemia, hypercho-
lesterolemia, and obesity) in patients with psoriasis, in
particular in those with severe and widespread forms
(Kimball and Wu, 2009; Langan et al., 2012; Yeung et al.,
2013). However, most of these studies were hospital-based
and investigated selected patient groups, and multiple biases
including publication bias must be considered when
interpreting them (Nijsten and Wakkee, 2009; Stern and
Nijsten, 2012). Further, the results in the published literature
are not unambiguous. For example, in the population-based
Rotterdam Study and in the National Health and Nutrition
Examination Survey, psoriasis was not associated with the
risk for coronary heart disease, stroke, or heart failure
(Dowlatshahi et al., 2013a), nor with fasting glucose (Love
et al., 2011), and in the Nurses’ Health Study the association
of psoriasis with T2D was very modest and only among
younger patients (Li et al., 2012). Finally, in line with our
results, meta-analyses indicated that the association of
psoriasis with cardiometabolic diseases is rather modest and
driven by severe cases (Armstrong et al., 2013; Ma et al.,
2013; Miller et al., 2013; Samarasekera et al., 2013). The
degree to which the association is directly attributable to
psoriasis remains controversial.
Although providing sufficient sample sizes and statistical
power, routine data from health insurance databases com-
monly suffer from incomplete information on important
confounders and potential detection, diagnostic, and observa-
tion bias (Swart et al., 2014). In turn, population-based cross-
sectional studies capture many outcomes and risk factors
but are often underpowered to analyze diseases with a low
prevalence and do not allow to make causal inference, nor to
establish the time sequence of events. In this paper, we have
used both approaches in a complementary manner, and have
analyzed primary cross-sectional data from the well-charac-
terized KORA survey as well as secondary prospective data
from the allgemeine ortskrankenkasse Saxony administrative
health care database. In the cross-sectional analysis, psoriasis
was significantly associated with T2D and MI, and no
substantial attenuation upon adjustment for multiple possible
confounders was observed.
In line with the results from the cross-sectional analysis,
after adjusting for major known risk factors in the prospective
cohort study for psoriasis at large after a median follow-up time
of 6 years, we observed a moderately increased RR for incident
T2D and MI, as well as an increased risk for AP, which
translates into estimated excess risks of 18, 11, and 3 cases of
T2D, AP, and MI, respectively, per 10,000 person-years.
A recent in silico analysis on 363 SNPs in 4,482 psoriasis
cases and 7,463 controls reported statistically significant
associations of psoriasis with seven SNPs primarily implicated
in dyslipidemia, hypertension, and CAD (Lu et al., 2013). In
our more comprehensive genetic approach including both
large-scale GWAS data for psoriasis and CAD as well as high-
density genotyping data for roughly 100,000 cardiometabolic
candidate loci, we did not observe robust associations of
psoriasis with genetic risk markers primarily associated with
cardiometabolic risk factors and related end points, including
CAD and T2D. On a similar note, genetic psoriasis loci
displayed no evidence for association with CAD in the
coronary artery disease genome-wide replication and
meta-analysis (CARDIoGRAM) data set with 4 20,000 CAD
cases andB60,000 controls, except for very modest effects of
markers tagging the HLA-Cw6 allele. It has to be kept in mind,
though, that we focused on relatively common genetic varia-
tion. Growing evidence indicates that inflammation partici-
pates centrally in all stages of CAD and that thus variations in
MHC genes, which regulate inflammation and T-cell res-
ponses, might have effects across inflammatory traits. In
particular, BTNL2, which has been linked with various
immune-related diseases (Clancy et al., 2010; Jin et al.,
2011; Valentonyte et al., 2005), probably functions as a
T-cell costimulatory molecule. Furthermore, T-cell activation
regulated by costimulatory molecules has been implicated in
both psoriasis and CAD (Lahoute et al., 2011). Of note, we
focused on common variants, and additional studies are
warranted to assess the significance of rare genetic variants.
Given the lack of evidence for a joint genetic basis of
psoriasis and cardiometabolic traits and the consistently
observed ‘‘dose–response’’ relationship, we speculate that
shared non-genetic risk factors not captured in our analysis
and/or an increased inflammatory status of (severe) psoriatics
might contribute to the slightly increased risk for
comorbidities—e.g. inflammatory cytokines such as interleu-
kins and tumor necrosis factor-alpha, which increase oxidative
stress and drive insulin resistance (Dowlatshahi et al., 2013b).
The latter hypothesis would also be supported if early and
efficient psoriasis treatment lowered risk for comorbidities in a
prospective setting. Some support for this hypothesis is
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provided by a recent large retrospective analysis demon-
strating a reduced risk for T2D in patients with RA or
psoriasis who had received a TNF inhibitor (Solomon et al.,
2011), compared with patients on other disease-modifying
antirheumatic drugs. However, it has to be considered that
even for severe psoriasis the excess risks for cardiometabolic
diseases reported and observed here are very modest in
absolute terms, and that, so far, the potential impact of early
intervention with antipsoriatic agents has not been sufficiently
investigated.
Strengths and limitations
The major strengths of our epidemiological analysis are the
use of both a cross-sectional and a prospective population-
based approach. In the cross-sectional analysis, psoriasis
assessment and cardiometabolic risk profiling were stringent,
known potential confounders were taken into account, and
both soft and hard end points were analyzed. However, the
number of patients with psoriasis and cardiovascular events
was modest, and no stratification by psoriasis disease severity
was possible. The prospective cohort was sufficiently powered
to track and compare incident disease events in health care
beneficiaries with and without psoriasis, but the observation
period was relatively short. As no direct information on
disease severity was available, systemic therapy was used as
a surrogate marker. Further, although health administrative
data appear to be rather reliable for MI and T2D (Muggah
et al., 2013), and we used stringent outcome definitions, the
remaining limitations of disease ascertainment accuracy and
surveillance bias must be taken into account. One related
limitation is that exact time-to-event data could not be inferred
from the database utilized. We therefore assumed that every
participant adds 6 years of person-time when estimating
excess risks, which may be an overestimation and may thus
lead to a conservative estimate of the true excess risk.
Conclusions
Psoriasis at large appears to be an independent yet modest risk
factor for T2D and MI. For the subgroup of patients with
severe psoriasis, however, risk increments are considerably
higher. Thus, although on a population level the association
between severe psoriasis and CVD is rather modest and the
increase in absolute disease risk is minor, this risk might be
clinically relevant in individual patients. The excess comor-
bidity cannot fully be attributed to major known environ-
mental/lifestyle determinants of MI and T2D risk and appears
not to be due to shared genetic risk factors. Prospective and
sufficiently large cohort studies are needed to further clarify
the relationship between psoriasis and cardiometabolic traits,
and randomized controlled trials should test whether and
which psoriasis treatment has beneficial effects regarding
comorbidity risk.
METHODS
Study samples
KORA sample. Within the Monitoring of Trends and Determi-
nants in Cardiovascular Disease/KORA, southern Germany)
framework, different population-based surveys were performed.
The present analysis included KORA-C, which is a subset
of the KORA S3 as well as the KORA F4 survey conducted in
1994/95 and 1999/2001, respectively. The design and selection
criteria for these surveys have been described previously
(Holle et al., 2005). Participants received a standardized
interview and a self-administered questionnaire to gather informa-
tion on medical history, and a physical and dermatological (F4)
examination was performed and blood was drawn. Additional
information on data ascertainment strategy of the KORA F3 and
F4 study is provided (see Methods section in this article’s
Supplementary Data online). A total of 4,185 individuals with
full phenotypic information were used for the present cross-
sectional analysis.
German Health insurance beneficiaries. For the prospective
cohort analyses relating psoriasis to incident T2D and MI, we
utilized the allgemeine ortskrankenkasse Saxony database, an
anonymized population-based administrative health care data-
base, which holds complete information on outpatient health care
(diagnoses according to the International Statistical Classification
of Diseases (ICD–10), treatment procedures according to Anato-
mical Therapeutic Chemical Classification–Code) and demo-
graphic characteristics (age and sex) of 2.4 million individuals
from the state of Saxony, Germany, from 2005 to 2012. All
individuals continuously insured until 2012 or until death were
included in the present analysis (n¼ 1,811,098).
CARDIoGRAM study. The CARDIoGRAM consortium com-
bines 14 GWAS for CAD with 422,000 CAD patients and
460,000 individuals free of CAD, as previously described in
detail elsewhere (Schunkert et al., 2011).
Psoriasis genetic case-control study. To investigate the associa-
tion of known CAD SNPs and psoriasis, GWAS data from 4,489
psoriasis cases and 8,240 control subjects of European Caucasian
descent recruited from Germany, UK, and the US were included
(Nair et al., 2009; Ellinghaus et al., 2010; Strange et al., 2010).
All participating studies were approved by relevant institutional
review boards, and all participants provided written or oral
consent for genetic research using protocols approved by the
relevant institutional body.
Epidemiological analyses
Descriptive characteristics. The Kolmogorov-Smirnov test was
used to assess the normality of continuous variables. Non-normally
distributed continuous variables are presented as median
(25th and 75th percentile), and categorical variables are pre-
sented as proportions stratified by psoriasis status. Differences by
psoriasis status were assessed using the Wilcoxon–Mann–Whit-
ney test for continuous variables and the w2-test for categorical
variables.
Cross-sectional analysis. The association of psoriasis status with
continuous (body mass index, waist circumference, systolic blood
pressure, diastolic blood pressure, total cholesterol-to-high-den-
sity lipoprotein cholesterol ratio, carotid intima-media thickness,
C-reactive protein, or leukocytes) and dichotomous (hypertension,
T2D, metabolic syndrome, MI, peripheral arterial disease, or AP)
cardiometabolic characteristics in the KORA study was
analyzed using multivariable adjusted linear and logistic
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regression models, respectively. All models were adjusted for sex
and age. Model 2 (‘‘fully adjusted model’’) additionally adjusted
for smoking status (never, former, current), years of education
(p9 years, 10 years, X11 years), alcohol intake (g per day),
physical activity (no activity, low activity, moderate activity, high
activity), systolic blood pressure, hypertension treatment (no, yes),
T2D (no, yes), T2D treatment (no, yes), and lipid-lowering
treatment (no, yes). In the sensitivity analysis, effect modification
by age was investigated by inclusion of interaction terms of age
and psoriasis status. All P-values were two-sided, and P-values
o0.05 were considered statistically significant. Statistical ana-
lyses were performed with SAS statistical analysis software
(version 9.3).
Longitudinal analysis. For analyzing the association of psoriasis
with incident cardiometabolic events in German Health Insur-
ance beneficiaries, prevalent psoriasis in 2005 and 2006 was
defined as the primary exposure variable. To minimize misclassi-
fication, we defined a priori that the ICD–10 code for psoriasis
(L40) had to be documented at least twice in 2005 and 2006 or
once in 2005 and 2006 and at least once in 2007 until 2012. If
the last documented psoriasis diagnosis was a rule-out diagnosis,
patients were considered nonexposed. For cardiovascular risk
factors and other potentially confounding comorbidities, analo-
gous internal validation methods were applied. Incident cardio-
metabolic events were identified through health insurance
records. Health Insurance beneficiaries entered the study in
2005–2006 and were followed up from 2007 (start of person
time) until the end of the follow-up period in 2012 (end of person
time). Outcomes of interest were incident MI (ICD–10 code I21–
I23), incident AP (ICD: I20), incident stroke (ICD: I63 and I64),
and incident T2D (ICD: E11) in 2007 through 2012. Incident
cases were defined as patients having no respective diagnosis
documented in 2005 and 2006, and documentation of the
respective ICD–10 code at least twice in 2007 until 2012. Patients
with prevalent MI or T2D in 2005/2006 were excluded. The
association between prevalent psoriasis (present in 2005/2006)
and new-onset cardiometabolic diseases after 2006 (until 2012)
was analyzed with generalized linear models using Poisson
regression with robust error variances. All models were adjusted
for sex and age. A second model was additionally adjusted
for prevalent hypertension (ICD: I10; no, yes), T2D (no, yes),
obesity (ICD: E66; no, yes), and for disorders of lipoprotein
metabolism and other lipidemias (ICD: E78; no, yes). We
attempted to deal with unmeasured disease severity by stratifica-
tion by psoriasis-specific medication; that is, data on systemic
therapy (including ultraviolet therapy, adalimumab, etanercept,
infliximab, acitretin, cyclosporine, fumaric acid, methotrexate
methotrexate, azathioprine, cyclosporine, and hydroxyurea)
were used to further differentiate psoriasis participants into those
with ‘‘mild’’ and those with ‘‘severe’’ psoriasis as reported
previously (Gelfand et al., 2006). In sensitivity analysis, effect
modification by age was investigated by inclusion of interaction
terms of age and psoriasis status. The statistical analyses were
performed with STATA data analysis and statistical software
(version 12.1).
Genetic analyses
In silicoanalysis. A composite list of variants reported to be
associated with psoriasis with genome-wide significance
(Po5 10 8) was compiled using the Catalogue of Published
GWAS (Hindorff et al.) and associated reference lists (Tsoi et al.,
2012). A total of 57 SNPs were then evaluated for association
with CAD in the CARDIoGRAM data set (Preuss et al., 2010). In
analogy, a total of 73 SNPs associated with CAD with genome-
wide significance (Hindorff et al.; Lieb and Vasan, 2013) were
tested for association with psoriasis in a meta-analysis of German,
UK, and US case-control GWAS data sets with a total of 4489
psoriasis cases and 8240 controls. Details of the meta-analysis
have been previously reported (Nair et al., 2009; Ellinghaus et al.,
2010). SNPTEST was used to associate the imputed dosage
for each SNP with psoriasis status separately in each study
sample with adjustment for the first three principal components
from a multidimensional scaling analysis of population stratifi-
cation. The association test results of those SNPs with relatively
high confidence (PROPER_Info40.4) were then meta-analyzed
with METAL using the inverse-variance method based on a fixed-
effect model. We had at least 96% power to detect an ORX1.2
for an SNP with X10% allele frequency, applying a lenient
significance threshold of Po0.01 as proposed by Ellinghaus et al.
(2012).
Proportion of psoriasis risk SNPs with a positive association with
CAD and vice versa. We assessed the proportion of psoriasis
risk-increasing alleles with a positive association with CAD (OR
41) and vice versa. We tested whether this proportion differed
from 0.5 (proportion of SNPs with an OR41 for CAD by chance)
using an exact binomial test as proposed elsewhere (Lieb et al.,
2013).
Metabochip study. A total of 927 German psoriasis patients and
3,713 controls were genotyped using the Metabochip, a custom
Illumina iSelect genotyping array of nearly 200,000 SNP markers,
which was designed to analyze and fine-map association signals
identified through GWAS meta-analyses of cardiometabolic traits
and to fine-map established loci (Voight et al., 2012). The patients
were recruited from tertiary dermatology clinics based at the
Technische Universita¨t Munich and the University of Kiel
(Ellinghaus et al., 2012); controls were derived from the
population-based KORA and POPGEN studies (Holle et al.,
2005; Krawczak et al., 2006).The genotyping and calling of the
Metabochip were performed using Illumina GenomeStudio
software. Genotype data of all subsamples underwent the same
basic quality control as detailed in the online supplement. After a
quality control procedure, 99,362 SNPs were analyzed. Within
the cleaned Metabochip data set, we performed two sets of
analyses: First, we related all 99,362 SNPs to psoriasis using a
logistic regression model, adjusting for sex and the first eight
principal components from the multidimensional scaling of
population stratification. Second, we looked in detail at regions
that have been previously reported to be associated with psoriasis.
From these regions, only four lead SNPs were directly genotyped
on the Metabochip. For the remaining previously reported
psoriasis regions, we investigated the surrounding regions
(±500 kb) of each previously reported psoriasis lead SNP and
reported the SNP with the lowest P-value. All association analyses
were performed in PLINK (Purcell et al., 2007). We applied a
suggestive and array-wide significance level of P¼ 5 10 6 and
P¼ 5.03 10 7, respectively. We had479% power to detect an
ORX1.25 for an SNP, assuming the allele frequency isX10% at
the 5 10 6 significance level.
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